Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: What are the benefits of avoiding blood pressure destabilization?

Hypertension

Volumn 45, Issue 1, 2005, Pages 92-97

  Grover, Steven A ^a   Coupal, Louis ^a   Zowall, Hanna ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Blood pressure; Cardiovascular disease

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SURVEY; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL MODEL; STROKE; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; CORONARY DISEASE; COST SAVINGS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; HYPERTENSION; INCIDENCE; LACTONES; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MODELS, CARDIOVASCULAR; OSTEOARTHRITIS; PREVALENCE; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SULFONAMIDES; SULFONES; UNITED STATES;

EID: 11244296690     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000149684.01903.b8     Document Type: Article

References (35)

1. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care. 2002;8:S383-S391.
2. Fitzgerald GA, Patrono C. The Coxibx, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. J Am Med Assoc. 2000;284:1247-1255.
4. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MS, Kvien TK, Schnitzer TJ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
5. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc. 2001;286:954-959.
6. Dalen JE. Selective COX-2 inhibitors, NSAIDs, aspirin, and myocardial infarction. Arch Intern Med. 2002;162:1091-1092.
7. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002;162:1099-1104.
8. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromoembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105-1110.
9. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002;162:1111-1115.
10. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast prostaglandin (PG), Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
11. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477-484.
12. Johnson AG, Nguyen TV, Day RO. Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289-300.
13. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM; SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95.
14. Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCESS VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients >65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
15. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease. A comparison of primary vs secondary prevention. Arch Intern Med. 1998;158:655-662.
16. Central Patient Registry and Coordinating Centre for the Lipid Research Ciinics. Reference Manual for the Lipid Research Clinics Prevalence Study. Volumes 1 and 2. Chapel Hill, NC: Department of Biostatistics, University of North Carolina; 1974.
17. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, Reference Manuals and Reports (CD-ROM). NHANES III. 1996. Hyattsville, Md: Centers for Disease Control and Prevention.
18. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med. 1999;159:593-600.
19. Department of Health and Human Services. Medicare Provider Analysis and Review Database. Washington, DC: US Department of Health and Human Services, Health Care Financing Administration; 1998.
20. Agency for Health Care Policy and Research. Healthcare Costs and Utilization Project, HCUP-3. Rockville, Md: US Department of Health and Human Services; 1998.
21. American Medical Association. Medicare RBRVS: The Physicians' Guide 1999. Chicago, Ill: American Medical Association; 1999.
22. Medical Economics Company. Drug Topics Red Book. Montvale, NJ: Medical Economics Company; 1998.
23. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc. 1991;265:3255-3264.
24. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
25. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH, Peto R, MacMahon S. Blood pressure, stroke, and coronary heart disease. Part II. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
26. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150:341-353.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc. 2000;283:1967-1975.
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc. 2002;288335:2981-2997.
29. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995;155:701-709.
30. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
31. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;1345:479-486.
32. Mamdani M, Juurlink D, Lee D, Rochon P, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751-1756.
33. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140-145.
34. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109:2068-2073.
35. White WB. Hypertension associated with therapies to treat arthritis and pain. Hypertension. 2004;44:123-124.